Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
4.740
+0.380 (8.72%)
At close: Mar 4, 2026, 4:00 PM EST
4.660
-0.080 (-1.69%)
After-hours: Mar 4, 2026, 7:49 PM EST
Nuvation Bio Stock Forecast
Stock Price Forecast
The 9 analysts that cover Nuvation Bio stock have a consensus rating of "Strong Buy" and an average price target of $11.22, which forecasts a 136.71% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $17.
Price Target: $11.22 (+136.71%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nuvation Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Maintains $10 → $7 | Hold | Maintains | $10 → $7 | +47.68% | Mar 3, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $12 → $13 | Buy | Maintains | $12 → $13 | +174.26% | Mar 3, 2026 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +132.07% | Feb 10, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $9 → $12 | Buy | Maintains | $9 → $12 | +153.16% | Jan 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $17 | Strong Buy | Maintains | $18 → $17 | +258.65% | Jan 12, 2026 |
Financial Forecast
Revenue This Year
177.86M
from 62.90M
Increased by 182.76%
Revenue Next Year
341.18M
from 177.86M
Increased by 91.83%
EPS This Year
-0.50
from -0.60
EPS Next Year
-0.07
from -0.50
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 226.1M | 424.6M | |||
| Avg | 177.9M | 341.2M | |||
| Low | 104.3M | 217.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 259.4% | 138.7% | |||
| Avg | 182.8% | 91.8% | |||
| Low | 65.8% | 22.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.25 | 0.23 | |||
| Avg | -0.50 | -0.07 | |||
| Low | -1.05 | -0.35 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.